Clinical application of TDM of vancomycin in treatment of severe sepsis
Objective To access the therapeutic drug monitoring(TDM)of vancomycin in the treatment of severe sepsis.Methods Patients with sepsis admitted to ICU of People's Hospital of Inner Mongolia Autonomous Region from June 2018 to Decem-ber 2021 were collected as research objects.They were divided into TDM group and non-TDM group according to whether or not TDM was applied.The white blood cell count,procalcitonin,C-reactive protein,neutrophil rate,serum creatinine,length of hospital stay and duration of vancomycin in the two groups after treatment were recorded to evaluate the clinical efficacy of the two groups.Results After treatment,there were no significant differences in WBC count,procalcitonin,C-reactive protein,neutrophil rate,hos-pital stay and vancomycin use time between the two groups.However,the mean values of serum creatinine(139.99±84.80)μmol/L,neutrophil rate(79.94±7.89)%and procalcitonin(3.72±5.73)ng/ml in TDM group were significantly lower than those in non-TDM group,with statistical significance(P<0.05).Conclusions TDM of vancomycin has a good guiding effect in the treatment of patients with severe sepsis,maintaining an effective drug concentration and reducing the risk of renal toxicity.
therapeutic drug monitoringvancomycinsevere sepsisclinical effect
国家科技期刊平台
NSTL
万方数据
